About Hepatocellular Carcinoma Drugs HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease. Technavio’s analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over... Research Beam Model: Research Beam Product ID: 2037744 3500 USD New
Global Hepatocellular Carcinoma Drugs Market 2017-2021
 
 

Global Hepatocellular Carcinoma Drugs Market 2017-2021

  • Category : Healthcare
  • Published On : September   2017
  • Pages : 86
  • Publisher : Technavio
 
 
 
About Hepatocellular Carcinoma Drugs

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

Technavio’s analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Bayer
• Eli Lilly
• Johnson and Johnson
• Pfizer

Other prominent vendors
• Bristol-Myers Squibb
• Celgene
• F. Hoffmann-la Roche
• Gilead
• GlaxoSmithKline
• Merck
• Novartis
• Salix Pharmaceuticals
• Transgene

Market driver
• Growing cases of hepatitis B and C infections
• For a full, detailed list, view our report

Market challenge
• Stringent government regulations and trial failure in the late stage of drug development
• For a full, detailed list, view our report

Market trend
• Increase in R&D activities for liver cirrhosis medication
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
• Market size and forecast
• Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by therapy
• Chemotherapy
• Brachytherapy
• Ablation therapy
PART 08: Geographical segmentation
• HCC drugs market in Americas
• HCC drugs market in EMEA
• HCC drugs market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Increase in R&D activities for liver cirrhosis medication
• Rise in awareness
PART 12: Vendor landscape
• Competitive scenario
PART 13: Key vendor analysis
• Bayer
• Eli Lilly
• Johnson and Johnson
• Pfizer
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
List of Exhibits?
Exhibit 01: Functions of liver
Exhibit 02: Causes of HCC
Exhibit 03: Global HCC drugs market
Exhibit 04: Global HCC drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global HCC drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global HCC drugs market segmentation based on therapies
Exhibit 10: Global HCC drugs market share as per therapies 2016 and 2021
Exhibit 11: Major types of chemotherapy
Exhibit 12: Global HCC chemotherapy drugs market 2016-2021 ($ millions)
Exhibit 13: NEXAVAR: Drug overview
Exhibit 14: STIVARGA: Drug overview
Exhibit 15: Global HCC brachytherapy drugs market 2016-2021 ($ millions)
Exhibit 16: Global HCC ablation therapy market 2016-2021 ($ millions)
Exhibit 17: Global HCC drugs market share by geography 2016 and 2021
Exhibit 18: Global HCC drugs market revenues by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: HCC drugs market in Americas 2016-2021 ($ millions)
Exhibit 21: Liver cancer scenario in the US 2016
Exhibit 22: Market scenario in EMEA
Exhibit 23: HCC drugs market in EMEA 2016-2021 ($ millions)
Exhibit 24: Top five countries with highest incidence of liver cancer
Exhibit 25: Market scenario in APAC
Exhibit 26: HCC drugs market in APAC 2016-2021 ($ millions)
Exhibit 27: Proportions of HBV and HCV-related HCC in APAC
Exhibit 28: Hepatitis C scenario 2016
Exhibit 29: Hepatitis B scenario 2016
Exhibit 30: Lifestyle disease effect on liver
Exhibit 31: Global liver transplants scenario 2014
Exhibit 32: Percentage distribution of transplants by organ in the US 1988-2016
Exhibit 33: Effects of chemotherapy drugs on human body
Exhibit 34: Competitive structure analysis of global HCC drugs market 2016
Exhibit 35: Strategic success factors of companies in global HCC drugs market
Exhibit 36: Bayer: Key highlights
Exhibit 37: Bayer: Strength assessment
Exhibit 38: Bayer: Strategy assessment
Exhibit 39: Bayer: Opportunity assessment
Exhibit 40: Eli Lilly: Key highlights
Exhibit 41: Eli Lilly: Strength assessment
Exhibit 42: Eli Lilly: Strategy assessment
Exhibit 43: Eli Lilly: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT